Leads Biolabs to Convene 31 Aug 2026 Board Meeting for H1 Results Review and Dividend Deliberation

Bulletin Express

Aug 19

Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has scheduled a board meeting for Monday, 31 August 2026. The agenda includes:

1. Reviewing and approving the interim financial results of Leads Biolabs and its subsidiaries for the six months ended 30 June 2026. 2. Considering a recommendation on the payment of an interim dividend, if any.

The meeting will be chaired by Dr. Kang Xiaoqiang, who serves concurrently as Chairman, Executive Director and Chief Executive Officer. The Board currently comprises nine directors: three executive directors (Dr. Kang Xiaoqiang, Dr. Lai Shoupeng, Mr. Zuo Honggang), three non-executive directors (Mr. Zhang Yincheng, Dr. Chen Renhai, Dr. Wu Fenglan) and three independent non-executive directors (Dr. Zhang Hongbing, Mr. Du Yilong, Ms. Du Jiliu).

The announcement underscores the company’s adherence to scheduled financial disclosures and governance practices ahead of publishing its interim results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1161859865"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161859865\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161859865?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 18:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161859865","market":"us","top_or_hot":-1,"title":"Leads Biolabs to Convene 31 Aug 2026 Board Meeting for H1 Results Review and Dividend Deliberation","media":"Bulletin Express","content":"<p>Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has scheduled a board meeting for Monday, 31 August 2026. The agenda includes:</p>\n<p>1. Reviewing and approving the interim financial results of Leads Biolabs and its subsidiaries for the six months ended 30 June 2026.  \n2. Considering a recommendation on the payment of an interim dividend, if any.</p>\n<p>The meeting will be chaired by Dr. Kang Xiaoqiang, who serves concurrently as Chairman, Executive Director and Chief Executive Officer. The Board currently comprises nine directors: three executive directors (Dr. Kang Xiaoqiang, Dr. Lai Shoupeng, Mr. Zuo Honggang), three non-executive directors (Mr. Zhang Yincheng, Dr. Chen Renhai, Dr. Wu Fenglan) and three independent non-executive directors (Dr. Zhang Hongbing, Mr. Du Yilong, Ms. Du Jiliu).</p>\n<p>The announcement underscores the company’s adherence to scheduled financial disclosures and governance practices ahead of publishing its interim results.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leads Biolabs to Convene 31 Aug 2026 Board Meeting for H1 Results Review and Dividend Deliberation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeads Biolabs to Convene 31 Aug 2026 Board Meeting for H1 Results Review and Dividend Deliberation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-19 18:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has scheduled a board meeting for Monday, 31 August 2026. The agenda includes:</p>\n<p>1. Reviewing and approving the interim financial results of Leads Biolabs and its subsidiaries for the six months ended 30 June 2026.  \n2. Considering a recommendation on the payment of an interim dividend, if any.</p>\n<p>The meeting will be chaired by Dr. Kang Xiaoqiang, who serves concurrently as Chairman, Executive Director and Chief Executive Officer. The Board currently comprises nine directors: three executive directors (Dr. Kang Xiaoqiang, Dr. Lai Shoupeng, Mr. Zuo Honggang), three non-executive directors (Mr. Zhang Yincheng, Dr. Chen Renhai, Dr. Wu Fenglan) and three independent non-executive directors (Dr. Zhang Hongbing, Mr. Du Yilong, Ms. Du Jiliu).</p>\n<p>The announcement underscores the company’s adherence to scheduled financial disclosures and governance practices ahead of publishing its interim results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1161859865","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161859865","pubTimestamp":1787135308,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has scheduled a board meeting for Monday, 31 August 2026. The agenda includes: 1. Reviewing and approving the interim financial results of Leads...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"领导 Biolabs 于 2026 年 8 月 31 日召开董事会会议，审查上半年业绩并审议股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has scheduled a board meeting for Monday, 31 August 2026. The agenda includes:\n1. Reviewing and approving the interim financial results of Leads Biolabs and its subsidiaries for the six months ended 30 June 2026.  \n2. Considering a recommendation on the payment of an interim dividend, if any.\nThe meeting will be chaired by Dr. Kang Xiaoqiang, who serves concurrently as Chairman, Executive Director and Chief Executive Officer. The Board currently comprises nine directors: three executive directors (Dr. Kang Xiaoqiang, Dr. Lai Shoupeng, Mr. Zuo Honggang), three non-executive directors (Mr. Zhang Yincheng, Dr. Chen Renhai, Dr. Wu Fenglan) and three independent non-executive directors (Dr. Zhang Hongbing, Mr. Du Yilong, Ms. Du Jiliu).\nThe announcement underscores the company’s adherence to scheduled financial disclosures and governance practices ahead of publishing its interim results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}